Navigation Links
BioMarin Announces Third Quarter 2011 Financial Results
Date:10/27/2011

-701 for Pompe Disease: The Phase I/II trial in Pompe patients is an open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and clinical activity of BMN-701 administered as an intravenous infusion every two weeks at doses of 5 mg/kg, 10 mg/kg and 20 mg/kg.  The company has completed enrollment of patients in the 10 mg/kg dose cohort.  Top-line results are expected in the second half of 2012.
  • BMN-673 (PARP inhibitor):  BioMarin has two ongoing trials for BMN-673: a Phase I/II open-label trial of once daily, orally administered BMN-673 for advanced or recurrent solid tumors and a Phase I, two-arm, open-label, dose escalation study for BMN-673 for the treatment of patients with advanced hematological malignancies.  Top-line results for both studies are expected in the second half of 2012.

  • Preclinical Programs

  • BMN-111 for Achondroplasia: BioMarin expects to file an IND in the fourth quarter of 2011 and initiate a Phase I trial in the first quarter of 2012.  BMN-111 is an analog of C-type Natriuretic Peptide (CNP), a small cyclic peptide that is a positive regulator of bone growth.  There are approximately 18,000 to 24,000 patients in the U.S. and Europe, an estimated 25 percent of which could be candidates for treatment with a product like BMN-111.
  • Other early stage programs: BioMarin is working on multiple additional early development opportunities.

  • Non-GAAP Financial Information and ReconciliationThe above results for the three and nine months ended September 30, 2011 and September 30, 2010 and financial guidance for the year ending December 31, 2011 are presented both as determined in accordance with GAAP and on a non-GAAP basis. As used in this release, non-GAAP income is based on GAAP Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) adjusted to exclude non-cash stock compensation expense, continge
    '/>"/>

    SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. BioMarin to Present at the UBS Global Life Sciences Conference
    2. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
    3. BioMarin to Present at the Baird Health Care Conference
    4. BioMarin to Present at the Wedbush Life Sciences Conference
    5. BioMarin Announces Second Quarter 2011 Financial Results
    6. BioMarin to Host Second Quarter 2011 Financial Results Conference Call and Webcast on Thursday, July 28 at 5:00 p.m. ET
    7. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
    8. BioMarin to Present at the William Blair Growth Stock Conference
    9. BioMarin to Present at the Jefferies Global Healthcare Conference
    10. BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
    11. BioMarin Announces First Quarter 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/14/2014)... , July 14, 2014 Synthetic ... technology partnership with global bioengineering leader DNA2.0, ... for quick-to-market products. The integration ... machine learning optimization technologies, such as ProteinGPS™ ... process of engineering proteins in the Pareto ...
    (Date:7/14/2014)... , July 14, 2014 BioAdaptives, Inc. ... , Chairman has assumed the roles of President and ... of Ferris Holding, Inc., the company that licensed its ... and its financial supporter. "Mr. ... our early transition as a privately held entity to ...
    (Date:7/13/2014)... 13, 2014 Auf ... Tokio veranstalteten F&E-Tagung meldete Astellas ... Neuausrichtung seines Forschungsrahmenprogramms. Die Tagung bot Astellas ... fortgeschrittenen klinischen Programme und die Konzernstrategie des ... bestand darin, aktuelle Meldungen zu den Astellas-Initiativen ...
    Breaking Medicine Technology:Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 2Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 3BioAdaptives Prepares for Next Step 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 3Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 4
    ... Calif., Nov. 14 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... devices,for the minimally invasive treatment of venous reflux ... using the VNUS,ClosureFAST catheter were presented today at ... VNUS ClosureFAST(TM) catheter is an endovenous,radiofrequency (RF) ablation ...
    ... Multi-national study compared FORTEO and the currently ... the treatment of Glucocorticoid-Induced Osteoporosis, INDIANAPOLIS, ... The New England Journal of Medicine, showed ... 1-34, teriparatide [rDNA,origin] injection) significantly increased lumbar ...
    Cached Medicine Technology:Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium 2Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium 3FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis 2FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis 3FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis 4FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis 5FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis 6
    (Date:7/14/2014)... 14, 2014 The Cabin Chiang Mai, ... new Alumni Community website – a free ... help them maintain lifelong recovery wherever they live in ... clients the tools to help them maintain their recovery ... part of any reputable treatment programme. As a chronic ...
    (Date:7/14/2014)... (PRWEB) July 14, 2014 ... Protocol book review recently updated by Vkool.com, ... of a wide range of simple and ... endometriosis including:,     Increasing ... and dairy products ,     Increasing fiber ...
    (Date:7/14/2014)... 2014 Reha Technology today announced ... portable and full-featured upper extremity robotic trainer that ... interactive games and challenges in a lightweight and ... , Armotion combines a variety of ... maximize the therapy effect for patients with severe ...
    (Date:7/14/2014)... July 14, 2014 Love Digits LLC ... called Love Digits. The App brings ancient astrology to ... to quantify their compatibility using a five-star rating system. ... people can instantaneously test their compatibility for love and ... , The app’s five-star rating system generates a weighted ...
    (Date:7/14/2014)... MT (PRWEB) July 14, 2014 New ... Women's Voices for the Earth examines toxic ... majority of women nationwide, including specific chemicals that may ... as additives and fragrances that may put women’s health ... science and research, Alexandra Scranton , the potential ...
    Breaking Medicine News(10 mins):Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 2Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 3Health News:Endometriosis Bible and Violet Protocol Book Review Exposes Zoe Brown's Endometriosis Treatment Guide – Vkool.com 2Health News:Endometriosis Bible and Violet Protocol Book Review Exposes Zoe Brown's Endometriosis Treatment Guide – Vkool.com 3Health News:Reha Technology Launches the Armotion™, a Device for the Rehabilitation of the Upper Extremity 2Health News:Love Digits, Numerical Approach to Modern Love, Now Available on iTunes 2Health News:Love Digits, Numerical Approach to Modern Love, Now Available on iTunes 3Health News:New Patent Analysis Shows Toxic Risk From Tampons 2Health News:New Patent Analysis Shows Toxic Risk From Tampons 3Health News:New Patent Analysis Shows Toxic Risk From Tampons 4Health News:New Patent Analysis Shows Toxic Risk From Tampons 5
    ... this country has nearly doubled in the past 20 years. ... therapists are charged with the task, but many are falling ... lack scientific rigor. This is in part because many of ... for-profit training centersare not grounded in science. A new ...
    ... , BOSTON, Oct. 2 Hess Corporation will present two $50,000 ... Foundation and the other to Children,s Hospital Boston,s Trauma Program -- ... Red Sox, home opening day. Aric Morrison, a Hess Retail regional ... , Hess Corporation promised to donate $500 for every home run ...
    ... award today for excellence in research, advancing oral health ... will receive the 2009 American Dental Association,s (ADA) Gold Medal ... formal presentation during a meeting of the ADA,s House ... once every three years, the award honors individuals who contribute ...
    ... highest honor on Kenneth L. Kalkwarf, D.D.S. at its 150th ... American Dental Association (ADA) will honor Kenneth L. Kalkwarf, D.D.S., ... Session and World Marketplace Exhibition in Honolulu. The Distinguished Service ... individual. , ADA President John S. Findley, D.D.S., ...
    ... 2 Beginning October 1st, The Peninsula Chicago will dedicate ... Month and several cancer research and education organizations. , "We ... cancer in some way and this is why we at ... Zec, general manager of The Peninsula Chicago. "In addition to ...
    ... 2 Pillar Capital is pleased to announce its acquisition ... to an order of the Bankruptcy Court for the District ... free and clear of claims. The Medico Labs business ... in 2000, manufactures and distributes private label and store brand ...
    Cached Medicine News:Health News:Where's the science? The sorry state of psychotherapy 2Health News:Hess Home Run Campaign a Hit for Kids with Medical Needs 2Health News:Hess Home Run Campaign a Hit for Kids with Medical Needs 3Health News:ADA's 2009 Gold Medal Award Presentation Set for 150th Annual Session 2Health News:Dental Educator to Receive the ADA Distinguished Service Award 2Health News:Dental Educator to Receive the ADA Distinguished Service Award 3Health News:The Peninsula Chicago Gives Back During Breast Cancer Awareness Month 2Health News:Pillar Capital Announces Acquisition of Medico Labs' Assets 2
    ... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
    ... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
    ... The Blue Line Wrist Control offers a ... wrist support for Carpal Tunnel Syndrome, tendinitis, ... the wrist. Careful design leaves fingers free ... wrist. Lightweight metal stay can be contoured ...
    Combination Oppenheimer with Knuckle Bender - to dorsiflex wrist and flex MCP joints; includes two attachments to extend/flex distal finger joints....
    Medicine Products: